Trending Stock News

Agios Pharmaceuticals, Inc. (AGIO) Reaches $75.11 52-Week High; Corecommodity Management Has Lowered By $811,840 Its American Wtr Wks Co New (AWK) Stake

The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) hit a new 52-week high and has $79.62 target or 6.00% above today’s $75.11 share price. The 9 months bullish chart indicates low risk for the $3.66B company. The 1-year high was reported on Jan, 15 by Barchart.com. If the $79.62 price target is reached, the company will be worth $219.72M more. The stock increased 3.54% or $2.57 during the last trading session, reaching $75.11. About 671,149 shares traded or 67.77% up from the average. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 8.52% since January 15, 2017 and is uptrending. It has underperformed by 8.18% the S&P500.

Corecommodity Management Llc decreased American Wtr Wks Co Inc New (AWK) stake by 57.3% reported in 2017Q3 SEC filing. Corecommodity Management Llc sold 10,148 shares as American Wtr Wks Co Inc New (AWK)’s stock rose 2.78%. The Corecommodity Management Llc holds 7,562 shares with $612,000 value, down from 17,710 last quarter. American Wtr Wks Co Inc New now has $14.42B valuation. The stock decreased 4.61% or $3.91 during the last trading session, reaching $80.83. About 4.00M shares traded or 315.64% up from the average. American Water Works Company, Inc. (NYSE:AWK) has risen 3.35% since January 15, 2017 and is uptrending. It has underperformed by 13.35% the S&P500.

Corecommodity Management Llc increased Atwood Oceanics Inc (NYSE:ATW) stake by 93,974 shares to 119,936 valued at $1.13M in 2017Q3. It also upped Technipfmc Plc stake by 24,225 shares and now owns 40,750 shares. Schlumberger Ltd (NYSE:SLB) was raised too.

Analysts await American Water Works Company, Inc. (NYSE:AWK) to report earnings on February, 20. They expect $0.66 earnings per share, up 15.79% or $0.09 from last year’s $0.57 per share. AWK’s profit will be $117.73M for 30.62 P/E if the $0.66 EPS becomes a reality. After $1.08 actual earnings per share reported by American Water Works Company, Inc. for the previous quarter, Wall Street now forecasts -38.89% negative EPS growth.

Investors sentiment increased to 1.05 in 2017 Q3. Its up 0.05, from 1 in 2017Q2. It improved, as 35 investors sold AWK shares while 185 reduced holdings. 46 funds opened positions while 186 raised stakes. 139.87 million shares or 0.09% less from 140.00 million shares in 2017Q2 were reported. Patten & Patten Tn owns 16,190 shares. Cambiar Llc accumulated 465,411 shares. Gulf Intll Bankshares (Uk) holds 0.06% or 57,882 shares. Ahl Limited Liability Partnership holds 34,267 shares or 0.05% of its portfolio. St Johns Management Limited Liability Company holds 0.02% or 400 shares in its portfolio. Proshare Limited reported 19,030 shares or 0.01% of all its holdings. Manufacturers Life The has 192,422 shares. Rhumbline Advisers invested in 0.06% or 351,240 shares. First Tru Advsrs Ltd Partnership reported 123,775 shares. Texas-based Argent Trust has invested 0.07% in American Water Works Company, Inc. (NYSE:AWK). Bnp Paribas Asset Mngmt, a France-based fund reported 473,419 shares. Wetherby Asset Management Incorporated owns 0.11% invested in American Water Works Company, Inc. (NYSE:AWK) for 8,858 shares. Indexiq Advsrs Limited Liability Company reported 102,283 shares or 0.36% of all its holdings. Pacific Global Investment Mngmt has invested 0.24% of its portfolio in American Water Works Company, Inc. (NYSE:AWK). The Massachusetts-based Baldwin Brothers Ma has invested 0.23% in American Water Works Company, Inc. (NYSE:AWK).

Among 12 analysts covering American Water Works (NYSE:AWK), 2 have Buy rating, 0 Sell and 10 Hold. Therefore 17% are positive. American Water Works had 27 analyst reports since October 15, 2015 according to SRatingsIntel. The company was downgraded on Wednesday, April 26 by Robert W. Baird. Barclays Capital maintained American Water Works Company, Inc. (NYSE:AWK) rating on Tuesday, September 6. Barclays Capital has “Overweight” rating and $81 target. Robert W. Baird maintained it with “Hold” rating and $82.0 target in Friday, August 25 report. The stock of American Water Works Company, Inc. (NYSE:AWK) earned “Neutral” rating by Northcoast on Thursday, May 25. The firm has “Neutral” rating by Macquarie Research given on Wednesday, January 18. As per Tuesday, December 20, the company rating was upgraded by Janney Capital. Boenning & Scattergood downgraded American Water Works Company, Inc. (NYSE:AWK) on Monday, June 6 to “Neutral” rating. The firm earned “Neutral” rating on Thursday, October 15 by Ladenburg Thalmann. The rating was downgraded by Guggenheim to “Neutral” on Tuesday, January 2. On Friday, October 14 the stock rating was initiated by Robert W. Baird with “Outperform”.

Since August 21, 2017, it had 0 buys, and 2 insider sales for $1.52 million activity. $273,626 worth of American Water Works Company, Inc. (NYSE:AWK) shares were sold by Lynch Walter.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $3.66 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Analysts await Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report earnings on February, 15. They expect $-1.65 earnings per share, down 23.13% or $0.31 from last year’s $-1.34 per share. After $-1.59 actual earnings per share reported by Agios Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 3.77% negative EPS growth.

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 41 analyst reports since July 23, 2015 according to SRatingsIntel. On Wednesday, August 2 the stock rating was upgraded by Leerink Swann to “Outperform”. Oppenheimer maintained the stock with “Buy” rating in Thursday, June 1 report. The rating was initiated by Credit Suisse on Thursday, January 21 with “Outperform”. The firm earned “Buy” rating on Sunday, November 19 by SunTrust. SunTrust maintained it with “Buy” rating and $80.0 target in Tuesday, October 3 report. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has “Outperform” rating given on Thursday, November 2 by Credit Suisse. As per Wednesday, March 2, the company rating was initiated by Janney Capital. The firm has “Buy” rating by Needham given on Monday, October 24. On Monday, November 9 the stock rating was maintained by TH Capital with “Neutral”. The firm has “Outperform” rating given on Wednesday, May 18 by Credit Suisse.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *